Publications by authors named "Ross Overman"

19Publications

KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe.

Nat Commun 2019 06 13;10(1):2607. Epub 2019 Jun 13.

Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK.

View Article and Find Full Text PDF
June 2019

A Chemical-Genetic Approach to Generate Selective Covalent Inhibitors of Protein Kinases.

ACS Chem Biol 2017 06 8;12(6):1499-1503. Epub 2017 May 8.

Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca , Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom.

View Article and Find Full Text PDF
June 2017

Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3.

J Am Chem Soc 2016 08 11;138(33):10554-60. Epub 2016 Aug 11.

Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.

View Article and Find Full Text PDF
August 2016

Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.

Structure 2014 Dec 20;22(12):1764-1774. Epub 2014 Nov 20.

Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. Electronic address:

View Article and Find Full Text PDF
December 2014

Completing the structural family portrait of the human EphB tyrosine kinase domains.

Protein Sci 2014 May 11;23(5):627-38. Epub 2014 Mar 11.

AstraZeneca PLC, Alderley Park, Cheshire, SK10 4TG, United Kingdom.

View Article and Find Full Text PDF
May 2014